This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

This study has been completed.
Information provided by:
Emergent BioSolutions Identifier:
First received: March 25, 2009
Last updated: November 20, 2012
Last verified: April 2009
The purpose of this study is to assess the safety and efficacy of treatment of non-cutaneous T-cell lymphoma with treatment with CD4.

Condition Intervention Phase
T Cell Lymphoma Biological: HuMax-CD4 Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Refractory or Relapsed Non-Cutaneous CD4+ T-Cell Lymphoma

Resource links provided by NLM:

Further study details as provided by Emergent BioSolutions:

Primary Outcome Measures:
  • Efficacy as measured by survival and time to disease progression [ Time Frame: 12 months ]

Enrollment: 21
Study Start Date: August 2005
Study Completion Date: December 2008
Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CD4
Open label treatment arm
Biological: HuMax-CD4
Active treatment

Detailed Description:

The study is closed and all subjects have completed treatment.

The study is to evaluate the safety and efficacy of Humax CD4 with CHO vs CHO alone in subjects with non-cutaneous T cell lymphoma. The primary efficacy will be evaluated by time to relapse.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnostic biopsy of non cutaneous T Cell lymphoma with positive phenotype
  • Relapsed or refractory to minimum of one course of chemotherapy
  • Study is closed to enrollment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00877656

Sponsors and Collaborators
Emergent BioSolutions
Study Chair: Abhay Patki, PhD Genmab
  More Information

Responsible Party: ICTM, Genmab Identifier: NCT00877656     History of Changes
Other Study ID Numbers: Hx-CD4-109
Study First Received: March 25, 2009
Last Updated: November 20, 2012

Additional relevant MeSH terms:
Lymphoma, T-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on September 19, 2017